Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

AIDS (London, England) - 27 Sept 2002

Valer Luisa, De Mendoza Carmen, De Requena Daniel González, Labarga Pablo, García-Henarejos Adolfo, Barreiro Pablo, Guerrero Francisca, Vergara Antonio, Soriano Vincent

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Administration Schedule
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Multicenter Studies as Topic

Share to Plasma

Share to Saquinavir

Source

Identifiers

PMID: 12351959
DOI: 10.1097/00002030-200209270-00016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.PMID 12351959Read ↗

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An updateSemantic proximity Read ↗

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.Semantic proximity Read ↗

An updated guide to genotype interpretation.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

Development of a genotyping flow sheet for appropriate antiretroviral therapy.Semantic proximity Read ↗

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.Semantic proximity Read ↗

Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.Semantic proximity Read ↗

Baseline HIV genotype drug resistance testing: is it time for more or less?Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.Semantic proximity Read ↗

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.